Rachel R. Kroe

Catalysis and Function of the p38α·MK2a Signaling Complex

C. Pargellis, B. Werneburg, S. Lukas, 2004 .

Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: development of a flow-cytometry-based receptor occupancy assay.

P. Reilly, J. Woska, D. Jeanfavre, 2003, Journal of immunological methods.

Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.

M. Hao, K. Qian, C. Pargellis, 2008, Bioorganic & medicinal chemistry letters.

Discovery and characterization of a substrate selective p38alpha inhibitor.

C. Pargellis, B. Werneburg, S. Lukas, 2004, Biochemistry.

NUTS and BOLTS: applications of fluorescence-detected sedimentation.

T. Laue, Rachel R. Kroe, R. Kroe, 2009, Analytical biochemistry.

Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.

C. Pargellis, J. Regan, G. W. Peet, 2003, Journal of medicinal chemistry.

Agonist versus antagonist induce distinct thermodynamic modes of co-factor binding to the glucocorticoid receptor.

Elda Gautschi, N. Farrow, C. A. Grygon, 2007, Biophysical chemistry.

Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).

J. Madwed, C. Pargellis, P. Cirillo, 2003, Journal of medicinal chemistry.